1-[4-(5-bromopentyloxy)-2-hydroxy-3-propylphenyl]ethanone | 99453-85-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[4-(5-bromopentyloxy)-2-hydroxy-3-propylphenyl]ethanone
• 英文别名: 4'-<(5-bromopentyl)oxy>-3'-propyl-2'-hydroxyacetophenone；5-(2-n-propyl-3-hydroxy-4-acetylphenoxy)-1-bromopentane；4-(5-bromopentyloxy)-2-hydroxy-3-propylacetophenone；4-(5-bromopentoxy)-2-hydroxy-3-propylacetophenone；5-(2-n-propyl-3-hydroxy-4-acetylphenoxy)-1-bromo-pentane；5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyl bromide；1-Bromo-5-[2-n-propyl-3-hydroxy-4-acetylphenoxy]-pentane；1-[4-(5-bromopentoxy)-2-hydroxy-3-propylphenyl]ethanone
• CAS: 99453-85-7
• 化学式: C₁₆H₂₃BrO₃
• 分子量: 343.261
• InChiKey: LPZBIKWTPVHBRX-UHFFFAOYSA-N

物化性质

• 熔点：
  172–180°C
• 沸点：
  458.2±45.0 °C(Predicted)
• 密度：
  1.262±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-羟基-4-氧代-4H-吡喃-2-羧酸甲酯 、 1-[4-(5-bromopentyloxy)-2-hydroxy-3-propylphenyl]ethanone 生成 methyl 5-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-4-oxo-4H-pyran-2-carboxylate
  参考文献：
  名称：

  MASATERU, MIYANO;SHONE, ROBERT L.

  摘要：

  DOI：
• 作为产物：
  描述：

  1,5-二溴戊烷 、 2,4-二羟基-3-丙基苯乙酮 在 potassium carbonate 作用下， 以 N-甲基乙酰胺 、 ethyl acetate n-hexane 为溶剂， 生成 1-[4-(5-bromopentyloxy)-2-hydroxy-3-propylphenyl]ethanone
  参考文献：
  名称：

  Aralkoxy and aryloxyalkoxy kojic acid derivatives

  摘要：

  这项发明涉及替代的芳基氧基和芳氧基烷氧基曲酸衍生物，这些衍生物可用作白三烯D.sub.4（LTD.sub.4）抑制剂，因此在治疗过敏、炎症症状和冠状血管收缩方面具有用途。

  公开号：

  US04644071A1

文献信息

• Di-and tetrahydronapthyl anti-allergy agents
  申请人：G.D. Searle & Co.

  公开号：EP0300404A3

  公开（公告）日：1990-07-18

  This invention relates to compounds of the formula: and the pharmaceutically acceptable salts thereof: wherein R¹ represents straight or branched chain alkyl having 2-4 carbon atoms; wherein R² represents hydrogen or straight or branched chain alkyl having 1-6 carbon atoms; wherein R³ represents hydrogen or straight or branched chain alkyl having 1-3 carbon atoms; wherein R⁴ and R¹⁰ are different and represent H or n-propyl; wherein X represents an interger from 2 to 5; wherein R⁵ is hydrogen, or acts with R⁷ to produce an additional carbon-­carbon bond between C₁ and C₂; wherein R⁶ represents hydrogen or -Z-COOR⁹, wherein Z is either absent or represents straight or branched chain alkyl or alkenyl having 1-5 carbon atoms; and R⁹ represents hydrogen, pharmaceutically acceptable cations, or straight or branched chain alkyl having 1-6 carbon atoms; wherein R⁷ is hydrogen, or acts together with R⁵ to form an additional carbon-carbon bond between C₁ and C₂, or acts together with R⁸ to form when R⁸ is oxygen; wherein R⁸ is hydrogen, -O-R¹¹, or oxygen, such that when R⁸ is oxygen, R⁸ acts together with R⁷ to form and wherein R¹¹ is straight or branched chain alkyl having 1-4 carbon atoms. The di- and tetrahydronaphthyl compounds of this invention are pharmacologically active as leukotriene D₄ (LTD₄) antagonists and are useful as anti-­inflammatory and anti-allergy agents.

  本发明涉及以下化合物的公式：及其药学上可接受的盐：其中R¹代表具有2-4个碳原子的直链或支链烷基；其中R²代表氢或具有1-6个碳原子的直链或支链烷基；其中R³代表氢或具有1-3个碳原子的直链或支链烷基；其中R⁴和R¹⁰不同，代表H或正丙基；其中X代表从2到5的整数；其中R⁵为氢，或与R⁷作用以在C₁和C₂之间产生额外的碳-碳键；其中R⁶代表氢或-Z-COOR⁹，其中Z要么不存在，要么代表具有1-5个碳原子的直链或支链烷基或烯烃基；R⁹代表氢、药学上可接受的阳离子，或具有1-6个碳原子的直链或支链烷基；其中R⁷为氢，或与R⁵一起作用以在C₁和C₂之间形成额外的碳-碳键，或与R⁸一起作用当R⁸为氧时；其中R⁸为氢、-O-R¹¹，或氧，当R⁸为氧时，R⁸与R⁷一起形成，其中R¹¹为具有1-4个碳原子的直链或支链烷基。本发明的二氢和四氢萘基化合物在药理学上作为白三烯D₄（LTD₄）拮抗剂具有药理活性，并可用作抗炎和抗过敏药剂。
• Thiadiazole compounds as antagonists of SRS-A
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US04855310A1

  公开（公告）日：1989-08-08

  Novel heterocyclic compounds shown by the general formula ##STR1## or the pharmaceutically acceptable salts thereof useful as medicament in particular as antagonist of slow reacting substance of anaphylaxis (SRS-A).

  新颖的杂环化合物，其一般公式为##STR1##或其药学上可接受的盐，可用作药物，特别是作为过敏性反应缓慢物质（SRS-A）的拮抗剂。
• Substituted dihydrobenzopyran-2-carboxylates
  申请人：G. D. Searle & Co.

  公开号：US04565882A1

  公开（公告）日：1986-01-21

  The invention relates to substituted dihydrobenzopyrans carboxylates of the formula: ##STR1## wherein A is a methylene chain having 1-10 carbon atoms, inclusive, optionally substituted by hydroxy; wherein V is: (a) hydrogen; (b) hydroxy; (c) .dbd.O; or (d) R.sub.6 CH.sub.2 O--; wherein R.sub.1 is: (a) --COCH.sub.3 ; (b) --CHOHCH.sub.3 ; (c) --C.sub.2 H.sub.5 ; (d) -hydrogen; or (e) --COOC.sub.2 H.sub.5 wherein R.sub.2 is: (a) -hydrogen; (b) -hydroxy; or (c) R.sub.12 CH.sub.2 CO.sub.2 --; wherein R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 each of which may be the same or different, are: (a) hydrogen; (b) lower-alkyl having 1-6 carbon atoms inclusive; or (c) allyl; wherein R.sub.5 is: (a) hydrogen; or (b) R.sub.7 CH.sub.2 C(O)--; wherein R.sub.13 is hydrogen, hydroxy, alkoxy of 1 to 6 carbon atoms inclusive, or --OM wherein M is an alkali metal, alkyl of 1 to 6 carbon atoms, inclusive, or NR.sub.8.sup..sym. R.sub.9 R.sub.10 R.sub.11, or HNR.sub.8.sup..sym. R.sub.9 R.sub.10, or the pharmacologically acceptable addition salts thereof, which are useful as leukotriene D.sub.4 (LTD.sub.4) inhibitors and therefore useful in the treatment of allergies and inflammatory conditions.

  该发明涉及一种具有以下结构的替代二氢苯并吡喃羧酸酯：其中A是具有1-10个碳原子的亚甲基链，可以选择性地被羟基取代；其中V是：(a) 氢；(b) 羟基；(c) .dbd.O；或(d) R.sub.6 CH.sub.2 O--；其中R.sub.1是：(a) --COCH.sub.3；(b) --CHOHCH.sub.3；(c) --C.sub.2 H.sub.5；(d) -氢；或(e) --COOC.sub.2 H.sub.5；其中R.sub.2是：(a) -氢；(b) -羟基；或(c) R.sub.12 CH.sub.2 CO.sub.2 --；其中R.sub.3、R.sub.4、R.sub.6、R.sub.7、R.sub.8、R.sub.9、R.sub.10、R.sub.11和R.sub.12中的每一个可以相同也可以不同，分别是：(a) 氢；(b) 具有1-6个碳原子的低碳烷基；或(c) 烯丙基；其中R.sub.5是：(a) 氢；或(b) R.sub.7 CH.sub.2 C(O)--；其中R.sub.13是氢、羟基、1至6个碳原子的烷氧基，或--OM，其中M是碱金属、具有1至6个碳原子的烷基，或NR.sub.8.sup..sym. R.sub.9 R.sub.10 R.sub.11，或HNR.sub.8.sup..sym. R.sub.9 R.sub.10，或其药理学上可接受的盐，这些物质可用作白三烯D.sub.4（LTD.sub.4）抑制剂，因此在过敏和炎症症状的治疗中有用。
• Leukotriene LTD.sub.4 and LTB.sub.4 antagonists
  申请人：G. D. Searle & Co.

  公开号：US04923891A1

  公开（公告）日：1990-05-08

  This invention encompasses compounds of Formula I ##STR1## and the pharmaceutically acceptable salts and geometrical and optical isomers thereof wherein: X, Y, and Z are each independently O or S with S optionally oxidized to S=O; Alk is straight or branched chain alkylene or hydroxyalkylene containing 1-6 carbon atoms; R.sub.1 is hydrogen or lower alkyl; n is 0 to 5; R.sub.2 is hydrogen, lower alkyl, cycloalkyl, --(CH.sub.2).sub.n --CO.sub.2 R.sub.1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy; and Ar is 5,6,7,8-tetrahydro-1-naphthalenyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, or lower alkanoyl. This invention is in the field of pharmaceutical agents which act as leukotriene D.sub.4 (LTD.sub.4) antagonists and includes embodiments which act as leukotriene B.sub.4 (LTD.sub.4) antagonists.

  本发明涵盖了式I的化合物及其药学上可接受的盐和几何和光学异构体，其中：X、Y和Z分别独立地为O或S，其中S可选择氧化为S=O；Alk为直链或支链烷基或含有1-6个碳原子的羟基烷基；R1为氢或低碳烷基；n为0至5；R2为氢、低碳烷基、环烷基、-(CH2)n-CO2R1、苯基、以卤素、低碳烷基或低碳烷氧基取代的苯基；Ar为5,6,7,8-四氢-1-萘基、苯基或以低碳烷基、羟基、低碳烷氧基或低碳酰基取代的苯基。本发明涉及作为白三烯D4（LTD4）拮抗剂的药物剂，包括作为白三烯B4（LTD4）拮抗剂的实施方式。
• Heterocyclic compounds, their production, and medicaments containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0181779A1

  公开（公告）日：1986-05-21

  Compounds of formula I and salts thereof are useful for the treatment and prophylaxis of allergic diseases. Production and use of the compounds is described.

  式 I 的化合物 及其盐类可用于治疗和预防过敏性疾病。本文介绍了这些化合物的生产和使用。